Literature DB >> 11883378

Naloxone prevents increased atrial natriuretic peptide release during regional myocardial ischaemia and stunning in awake dogs.

T P Weber1, C Raufbake, M A Grosse Hartlage, N Rolf, J Stypmann, H Van Aken, E Berendes, A Meissner.   

Abstract

BACKGROUND: Atrial natriuretic peptide (ANP) release is increased in patients with ischaemic left ventricular dysfunction. A beneficial effect of naloxone on recovery from myocardial stunning was shown previously. The aim of this study was to investigate the effects of naloxone on ANP release during regional myocardial ischaemia and stunning in awake dogs.
METHODS: Ten dogs were chronically instrumented for measurement of heart rate, left atrial, aortic, and left ventricular pressure (LVP), LV dP x dtmax/min(-1), and myocardial wall-thickening fraction. An occluder around the left anterior descending artery (LAD) allowed induction of reversible ischaemia in the LAD-perfused myocardium. Each dog underwent two ischaemic episodes (randomized crossover fashion; separate days): 10 min of LAD occlusion (1) after application of naloxone (63 microg kg(-1)), and (2) without naloxone. ANP levels were measured at baseline (BL) and at predetermined time points until complete recovery of myocardial stunning occurred.
RESULTS: LAD ischaemia-induced release of ANP (peak level: 182 (30) vs 27 (7) pg ml(-1) BL) only in the control group without naloxone. Between 1 and 180 min of reperfusion, ANP levels were significantly higher only in the control group (P<0.05).
CONCLUSION: Pre-ischaemic application of naloxone prevents this ischaemia-induced ANP-release in conscious dogs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11883378     DOI: 10.1093/bja/88.1.87

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  1 in total

1.  Naloxone Postconditioning Alleviates Rat Myocardial Ischemia Reperfusion Injury by Inhibiting JNK Activity.

Authors:  Anzhou Xia; Zhi Xue; Wei Wang; Tan Zhang; Tiantian Wei; Xingzhi Sha; Yixun Ding; Weidong Zhou
Journal:  Korean J Physiol Pharmacol       Date:  2014-02-13       Impact factor: 2.016

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.